http://orcid.org/0000-0002-2324-0248
References
- Kobayashi Y, Mitsudomi T. Not all EGFR mutations in lung cancer are created equal: perspectives for individualized treatment strategy. Cancer Sci. 2016;107:1179–86.
- Shi Y, Li J, Zhang S, Wang M, Yang S, Li N, et al. Molecular epidemiology of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology – Mainland China subset analysis of the PIONEER study. PLoS One. 2015;10:e0143515.
- Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S, et al. Mutations of growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol. 2005;23:2513–20.
- Fuchs E, Raghavan S. Getting under the skin of epidermal morphogenesis. Nat Rev Genet. 2002;3:199–209.
- Wacker B, Nagrani T, Weinberg J, Witt K, Clark G, Cagnoni PJ. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res. 2007;13:3913–21.
- Azuma Y, Hata K, Sai K, Udagawa R, Hirakawa A, Tohkin M, et al. Significant association between hand-foot syndrome and efficacy of capecitabine in patients with metastatic breast cancer. Biol Pharm Bull. 2012;35:717–24.
- Horinouchi Y, Sakurada T, Nakamura T, Tajima S, Nishisako H, Abe S, et al. Hypertension as a predictive factor of effect of bevacizumab in treatment of colorectal cancer. Yakugaku Zasshi. 2011;131:1251–7. (in Japanese).
- Tanaka H, Takahashi K, Yamaguchi K, Kontani K, Motoki T, Asakura M, et al. Hypertension and proteinuria as predictive factors of effects of bevacizumab on advanced breast cancer in Japan. Biol Pharm Bull. 2018;41:644–8.
- Imai T, Saeki Y, Sakai M, Kono M, Ohtani Y, et al. Adverse events associated with gefitinib treatment according to type of EGFR mutation in advanced non-small-cell lung cancer. J Japan Soc Hosp Pharm. 2018;54:717–20. (in Japanese).
- Eck MJ, Yun CH. Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer. Biochim Biophys Acta. 2010;1804:559–66.
- Okuda Y, Sato K, Sudo K, Hasegawa Y, Asano M, Miura H, et al. Low plasma concentration of gefitinib in patients with EGFR exon 21 L858R point mutations shortens progression-free survival. Cancer Chemother Pharmacol. 2017;79:1013–20.
- Baselga J, Rischin D, Ranson M, Calvert H, Raymond E, Kieback DG, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol. 2002;20:4292–302.
- Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378:113–25.